Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kingsoft Cloud Holdings Limited (KC) vs Eli Lilly And Co (LLY) Price & Performance

Kingsoft Cloud Holdings LimitedTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Kingsoft Cloud Holdings Limited vs Eli Lilly And Co — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Eli Lilly And Co trades at $1,177.75 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 383.8× Kingsoft Cloud Holdings Limited's market cap, and Eli Lilly And Co pays a 0.59% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Eli Lilly And Co for 93 Days on average.

KCLLY
Market Cap
$2.71B$1.04T
Volume
1,993,7653,064,878
Sector
TechnologyHealth
52-Week High
$18.21$1.28K
52-Week Low
$8.58$799.57
Typical Hold Time
12 Days93 Days
Enterprise Value
$3.03B$1.09T
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kingsoft Cloud Holdings Limited

Kingsoft Cloud (KC) trades at $9.26, up 0.33% with bearish technical indicators but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. Despite negative net margins, gross margins improved significantly to 15.05% as AI cloud services drive growth. Cash flow from operations reached $3.8 billion in 2025, though 2026 projections show negative net cash flow.

KC presents a compelling turnaround story with AI-driven growth potential, trading at attractive valuation multiples (P/S: 1.58, EV/EBITDA: 2,203). However, persistent losses and negative cash flow projections for 2026 pose significant execution risks. The 70% analyst buy rating and 60% upside potential must be weighed against the bearish technical picture and competitive cloud market dynamics.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KC
0% Buy100% Sell
Avg holding period · 12 Days
LLY
22% Buy78% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Kingsoft Cloud Holdings Limited

Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.

Read more on KC →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →